The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
-
Published:2024-02
Issue:
Volume:198
Page:113501
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Di Giacomo Anna Maria,
Lahn MichaelORCID,
Eggermont Alexander MM,
Fox Bernard,
Ibrahim RamyORCID,
Sharma Padmanee,
Allison James P.,
Maio MicheleORCID
Subject
Cancer Research,Oncology
Reference106 articles.
1. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade >/=2 immune-related adverse events in patients with cancer;Allouchery;J Immunother Cancer,2020
2. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium;Amaria;Lancet Oncol,2019
3. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies;Arce Vargas;Cancer Cell,2018
4. Ipilimumab10 mg/kg versus ipilimumab3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial;Ascierto;Lancet Oncol,2017
5. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献